Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients: Analysis of results from the CONSENT trial.

Li-Nong JiJing LiuJing YangYufeng LiLi LiangDalong ZhuQuanmin LiTianrong MaHaiyan XuYanlan YangJiaoe ZengBo FengShen QuYiming LiLizhen MaShanshan LinJianping WangWei LiWeihong SongXiaoxing LiYong LuoShugang XiMei LinYu LiuZerong Liang

Published in: Diabetes, obesity & metabolism (2018)

Metformin XR was non-inferior to metformin IR for the LSM change in HbA1c from baseline to week 16 and not superior to metformin IR for overall GI AE incidence during treatment of Chinese T2DM patients.

Keyphrases

type diabetes
end stage renal disease
chronic kidney disease
cardiovascular disease
newly diagnosed
risk factors
glycemic control
study protocol
prognostic factors
open label
metabolic syndrome
adipose tissue
phase ii
phase iii